Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status.

Gibson W, Green A, Bullard RS, Eaddy AC, Donald CD

Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Suite 309, Charleston, SC 29425, USA.

Inhibition of apoptosis is a critical pathophysiological factor that contributes to the development of prostate cancer. Recently, PAX2, a transcriptional regulator implicated in oncogenesis, has been demonstrated to be expressed by prostate cancer. However, its downstream molecular pathways for suppression of apoptosis, other than the tumor suppressor gene p53, have yet to be elucidated. Here, we examine the effects of inhibiting PAX2 expression by prostate cancer cells that differ in p53 gene status. These data collectively demonstrate that PAX2 inhibition results in cell death independent of p53, and that additional tumor suppressors or cell death pathways may be inhibited by PAX2 in prostate cancer cells.

Published 6 March 2007 in Cancer Lett, 248(2): 251-61.
Full-text of this article is available online (may require subscription).

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.